Predicting the treatment response of certolizumab for individual adult patients with rheumatoid arthritis: protocol for an individual participant data meta-analysis

Yan Luo1*, Konstantina Chalkou2, Ryo Yamada3, Satoshi Funada1,4, Georgia Salanti2 and Toshi A. Furukawa1

Abstract

Background: A model that can predict treatment response for a patient with specific baseline characteristics would help decision-making in personalized medicine. The aim of the study is to develop such a model in the treatment of rheumatoid arthritis (RA) patients who receive certolizumab (CTZ) plus methotrexate (MTX) therapy, using individual participant data meta-analysis (IPD-MA).

Methods: We will search Cochrane CENTRAL, PubMed, and Scopus as well as clinical trial registries, drug regulatory agency reports, and the pharmaceutical company websites from their inception onwards to obtain randomized controlled trials (RCTs) investigating CTZ plus MTX compared with MTX alone in treating RA. We will request the individual-level data of these trials from an independent platform (http://vivli.org). The primary outcome is efficacy defined as achieving either remission (based on ACR-EULAR Boolean or index-based remission definition) or low disease activity (based on either of the validated composite disease activity measures). The secondary outcomes include ACR50 (50% improvement based on ACR core set variables) and adverse events. We will use a two-stage approach to develop the prediction model. First, we will construct a risk model for the outcomes via logistic regression to estimate the baseline risk scores. We will include baseline demographic, clinical, and biochemical features as covariates for this model. Next, we will develop a meta-regression model for treatment effects, in which the stage 1 risk score will be used both as a prognostic factor and as an effect modifier. We will calculate the probability of having the outcome for a new patient based on the model, which will allow estimation of the absolute and relative treatment effect. We will use R for our analyses, except for the second stage which will be performed in a Bayesian setting using R2Jags.

Discussion: This is a study protocol for developing a model to predict treatment response for RA patients receiving CTZ plus MTX in comparison with MTX alone, using a two-stage approach based on IPD-MA. The study will use a new modeling approach, which aims at retaining the statistical power. The model may help clinicians individualize treatment for particular patients.

(Continued on next page)
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disease, for which we cannot currently expect complete cure. The drugs that can delay disease progression are known as disease-modifying anti-rheumatic drugs (DMARDs). There are 3 categories: conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs). bDMARDs can be further divided into several subtypes according to the target, among which the tumor necrosis factor (TNF) α inhibitors are the most classic and widely used.

Most RA patients undergo long-term treatment. According to the treat-to-target strategy proposed by the EULAR (European League Against Rheumatism) practice guideline [1], repeated assessment of disease activity should be performed every 3 to 6 months after a treatment is given, to evaluate the response and decide the next-step strategy: switching drugs, maintenance, tapering, or discontinuation. Hence, the disease course of RA is composed of many intervention-response loops. For the purpose of improving long-term prognosis, such as delaying the progression of bone fusion or functional deficiency, short-term intervention-response loops need to have beneficial outcomes [2].

To find the optimal treatment for a particular patient, it is necessary to personalize the treatment. It would be helpful if we could predict the probability of treatment response based on the patient’s genetic, biologic, and clinical features. However, common evidence in the form of randomized controlled trials (RCTs) or their meta-analyses (MAs) at the aggregate level only reports average results. The drug that works for the average patients might not work or even be harmful for a particular patient. Consequently, it is desirable to identify subgroups of patients associated with different treatment effects.

Individual participant data meta-analysis (IPD-MA) has been previously employed to develop prediction models for treatment effects [3–6]. Previous treatment response prediction models for RA were mainly based on observational studies [7–11]. Observational studies seem suited for predicting the absolute risk of an outcome, but it may be less satisfactory in estimating the relative risk between different drugs, because unknown confounders may persist even when we try to adjust for known confounders. On the other hand, though the population in RCTs is highly restricted hence may be less representative, data from RCTs are more rigorously collected and more likely to provide an unbiased estimate of the relative treatment effects [12]. The synthesis of RCT data via IPD-MA can increase the statistical power [13] and have been used to predict treatment response [6, 14–17]. To the best of the authors’ knowledge, such an approach has not been taken to predict treatment response in RA to date.

Our aim is to develop a prediction model of treatment effects based on individual characteristics of RA patients through IPD-MA. Since TNFα inhibitors are the most classic and widely used bDMARDs for RA, we will build a model for certolizumab (CTZ), a TNFα inhibitor with sufficient IPD data, in this study. We will first estimate the pooled average effect sizes for the primary and secondary outcomes using one-stage Bayesian hierarchical IPD-MA. The main objective of the study is to use a two-stage risk modeling approach to predict the individualized treatment effects interest [12]. The first stage is to build a multivariable model aiming to predict the baseline risk for a particular patient blinded to treatment. In the second stage, this baseline risk score will be used as a prognostic factor and an effect modifier in an IPD meta-regression model to estimate the individualized treatment effects of CTZ. We consider to validate and optimize the modeling approach in the present study, and plan eventually to expand it to an IPD network meta-analysis to compare several drug types (e.g., interleukin-6 inhibitors, anti-CD20 antibodies) as our future research perspective.

Methods
The present protocol has been registered within the PROSPERO database (provisional registration number ID#157595) and is being reported in accordance with the reporting guidance provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement [18] (see the checklist in Additional file 1). The proposed IPD-MA will be reported in accordance with the reporting guidance provided in the Preferred Reporting Items for Systematic Reviews and Meta-analyses of Individual Participant Data (PRISMA-IPD) statement [19]. Any amendments made to this protocol when conducting the study will be outlined and reported in the final manuscript.

Eligibility criteria
Studies will be selected according to the following criteria: patients, interventions, outcomes, and study design.
**Patients**
We will include adults (18 years or older) who are diagnosed with either early RA (2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria) [20, 21] or established RA (1987 classification criteria) [22]. Patients with inner organ involvement (such as interstitial lung diseases), vasculitis, or concomitant other systemic autoimmune diseases will be excluded. We will include both treatment-naïve patients and patients who have insufficient response to previous treatments. We will include patients with moderate to severe disease activity based on any validated composite disease activity measures. Patients who have already achieved remission or at low disease activity at baseline will be excluded. Patients who have used certolizumab (CTZ) within 6 months before randomization will be excluded.

**Interventions**
We will include RCTs which compare certolizumab (CTZ) plus methotrexate (MTX) with MTX monotherapy, regardless of doses. If a study compares CTZ with any csDMARDs, we will only include patients on CTZ + MTX or MTX from that study. Trials investigating the tapering or discontinuation strategy of CTZ will be excluded.

**Outcomes**
Our primary outcome is efficacy defined by disease states, which is achieving either remission (based on ACR-EULAR Boolean or index-based remission definition [23]) or low disease activity (based on either of the validated composite disease activity measures [24]: DAS28 (Disease Activity Score based on the evaluation of 28 joints) ≤3.2 [25], CDAI (Clinical Disease Activity Index) ≤ 10 [26], SDAI (Simplified Disease Activity Index) ≤ 11 [27]) at 3 months (allowance 2–4 months) after treatment, as a binary outcome. We choose it as our primary outcome because it is suggested as the indicator of the treatment target in both the practice guideline [1] and the guideline for conducting clinical trials in RA [2], and it has been shown to provide more information for future joint damage and functional outcomes compared to relative response (change from baseline) [28].

We have two secondary outcomes. One is efficacy defined by response (improvement from baseline), for which we will use the ACR response criteria ACR50 (50% improvement based on ACR core set variables) [29]. Another is adverse events (AEs). We will perform an IPD-MA separately for patients with all kinds of infectious AEs within 3 months since it is one of the most important AEs for biologic agents. We will also describe other noticeable AEs within 3 months reported in the trials. We will not make predictions models for the secondary outcomes.

**Study design**
We will include double-blind RCTs only. If there are crossover RCTs, only the data of the first phase will be used for analysis. Cluster RCTs, quasi-randomized trials, and observational studies will be excluded.

**Information source and literature search**
We will conduct an electronic search of Cochrane CENTRAL, PubMed, and Scopus from inception onwards, with the keywords: “rheumatoid arthritis,” “certolizumab” or “CDP870” “Cimzia”, “methotrexate” or “MTX,” without language restrictions. A draft search strategy is provided in Additional file 2. We will search WHO International Clinical Trials Registry Platform to find the registered studies. We will search the US Food and Drug Administration (FDA) reports to see if there are any unpublished reports from the pharmaceutical companies. For IPD, we will contact the company which markets certolizumab and request IPD through http://vivli.org. We will assess the representativeness of the IPD among all the eligible studies by investigating the potential differences between trials with IPD and those without IPD.

**Screening and selection procedure**
Two independent reviewers will screen the titles and abstracts retrieved from the electronic searches to assess for inclusion. If both reviewers agree that a trial does not meet eligibility criteria, it will be excluded. The full text of all the remaining articles will be obtained for further reading, and the same eligibility criteria will be applied to determine which to exclude. Any disagreements will be resolved through discussion with a third member of the review team.

**Data collection**

**At aggregate level**
Two reviewers will independently extract the information for all the included studies at aggregate level. A detailed data extraction template will be developed and piloted on 3 articles; after finalizing the items on the data extraction form, the 3 articles will be re-extracted. The main information includes intervention/control details, trial implementation features (e.g., completion year, randomized numbers, dropouts, follow-up length), baseline demographic and disease-specific characteristics, and outcomes of interested. The above information will be used for (1) exploring the representativeness of the trials with IPD among all the eligible trials and (2) confirming if the IPD is consistent with the reported results.

**At IPD level: for studies with IPD available**
When the IPD is ready to be used, we will identify the variables of interest before the analysis. The variables
regarding intervention, control, and outcomes are defined as the above in the “Eligibility criteria” section. With regard to patient or trial characteristics to be used as potential covariates in the prognostic model, based on the literature [30–32] and our clinical practice, we propose the following factors as candidates of potential prognostic factors (PFs, baseline factors that may affect the response regardless of the treatment) (Table 1), which will be used for baseline risk model development (see the “Predicting treatment effect for patients with particular characteristics: a two-stage model” section below). We will try to collect all the information listed in Table 1 from the data, but only available factors that have been recorded in the trials will be added into the model. We will decide in which type (e.g., continuous, categorical, binary, etc.) a covariate will be put into the model according to the distribution of that covariate after we obtain the data.

### Risk of bias assessment

Two independent reviewers will assess the risk of bias (RoB) for each included RCT according to “RoB 2 tool” proposed by the Cochrane group [34]. For the efficacy primary outcome, RCTs will be graded as “low risk of bias,” “high risk of bias,” or “some concerns” in the following five domains: risk of bias arising from the randomization process, risk of bias due to deviations from the intended interventions, missing outcome data, risk of bias in measurement of the outcome, and risk of bias in selection of the reported result. The assessment will be adapted for IPD-MA, i.e., as per the obtained data and not the conducted and reported analyses in the original publications. Finally, they will be summarized as an overall risk of bias according to the RoB 2 algorithm.

### Data analysis

Since our primary aim is to develop a prediction model and not to get a precise estimation of the treatment effects, all the analyses will be based on IPD only. Therefore, we will neither analyze aggregate data together nor investigate the robustness of the IPD-MA including aggregate data, for they are beyond the perspectives of the present study.

### Average relative treatment effect: IPD-MA

We first synthesize the data using one-stage Bayesian hierarchical IPD-MA [35]. We will estimate the average relative treatment effect in terms of odds ratio (OR) for efficacy.

Let $y_{ij}$ denote the dichotomous outcome of interest ($y_{ij} = 1$ for remission or low disease activity), for patient $i$ where $i = 1, 2, \ldots, n_i$ in trial $j$ out of $N$ trials, $t_{ij}$ be 0/1 for patient in control/intervention group, and $p_{ij}$ is the probability of having the outcome.

$$ y_{ij} \sim \text{Bernoulli}(p_{ij}) $$

$$ \log\left( \frac{p_{ij}}{1-p_{ij}} \right) = \logit(p_{ij}) = \alpha_j + \delta_j t_{ij} $$

$$ \delta_j \sim N(\delta, \tau^2) $$

where $\alpha_j$ is the log odds of the outcome for the control group, in trial $j$, which is independent across trials; $\delta_j$ is
the treatment effect (log OR), which we assume to be exchangeable across trials; δ is the summary estimate of the log-odds ratios for the intervention versus the control arm; and $r^2$ is the heterogeneity of δ across trials.

**Predicting treatment effect for patients with particular characteristics: a two-stage model**

**Data pre-processing** Within each study, the outcomes and the covariates will be evaluated for missing data, and we will further look at their distributional characteristics and correlations between the covariates (listed in the “At IPD level: for studies with IPD available” section). We will use multiple imputation methods for handling missing data [36]. We will consider data transformation for continuous variables to resolve skewness and re-categorization for categorical variables if necessary. If two or more variables are highly correlated, we will only retain the variable that is most commonly reported across studies and in the literature or the variable that has the least missing values.

**Stage 1: Developing a baseline risk model** In this step, we will build a multivariable model to predict the probability that a patient, given her or his baseline characteristics: a two-stage model

Predicting treatment effect for patients with particular characteristics: a two-stage model

In order to select the most appropriate model, we propose two approaches: (1) use previously identified prognostic factors and through discussions with rheumatologists to decide the subset of the most clinically relevant factors and estimate the coefficients using penalized maximum likelihood estimation shrinkage method and (2) use LASSO penalization methods for variable selection and coefficient shrinkage [38].

For each possible model, we will examine the sample size first, in order to assess the reliability of the model. We will calculate the events per variable (EPV) for our model, using all the categories of categorical variables and the degrees of freedom of continuous outcomes [39]. We will calculate efficient sample size for developing a logistic regression model [40]. Validation is essential in prediction model development. Since no external data is available, we can only use internal validation. Via resampling methods like bootstrap or cross-validation, we can estimate the calibration slope and c-statistic for each model, to indicate the ability of calibration and discrimination.

**Stage 2: Developing a meta-regression model for treatment effects** We use the same notation system as that in the “Average relative treatment effect: IPD-MA” section. The logit($r_{ij}$) from stage 1 will be used as a covariate in the meta-regression model, both as a prognostic factor and as an effect modifier. Let $\logit(r_{ij})^*$ denote the average of logit-risk for all the individuals in study j. The regression equation will be:

$y_{ij} \sim \text{Bernoulli}(p_{ij})$

$logit(p_i) = \left\{ \begin{array}{ll}
  a_j + b_{ij} \times \{ \logit(r_{ij}) - \logit(r_{0j}) \} & \text{if } t_{ij} = 0 \\
  a_j + \delta_j + g_{0j} \times \{ \logit(r_{ij}) - \logit(r_{0j}) \} + g_j \times \{ \logit(r_{0j}) - \logit(r_{00}) \} & \text{if } t_{ij} = 1
\end{array} \right.$

$\delta_j \sim N(\delta, r^2)$

$g_{0j} \sim N\left(\gamma_0, \sigma^2_{g0}\right)$

$g_j \sim N\left(\gamma, \sigma^2_g\right)$

$a_j$ is the log odds in the control group when a patient has a risk equal to the mean risk, which is assumed to be independent across trials. $g_{0j}$ is the coefficient of the risk score, while $g_j$ is the treatment effect modification of the risk score for the intervention group versus the control group; both are assumed to be exchangeable across trials and normally distributed about a summary estimate $\gamma_0$ and $\gamma$ respectively.

**Predicting the probability of having the outcome for a new patient** Assume a new patient $i$ who is not from any trial $j$ has a baseline risk score logit($r_i$) calculated
from stage-one. In order to predict the absolute logit-probability to achieve the outcome, we use:

$$\logit(p_i) = a + y_0 \times (\logit(\widetilde{r}_i) - \logit(r)), \text{ if } x_i = 0$$

$$\logit(p_i) = a + \delta + y_0 \times (\logit(\widetilde{r}_i) - \logit(r)) + \gamma \times (\logit(\widetilde{r}_i) - \logit(r)), \text{ if } x_i = 1$$

We would have estimated $\delta$, $y_0$, and $\gamma$ in the meta-regression stage. We will estimate $\logit(r)$ as the mean of $\logit(r_i)$ across all the individuals and studies. For $a$, we will estimate it by synthesizing all the control arms. Then, we can calculate the individual probability of the outcome both for the control and the intervention and estimate the predicted absolute and relative treatment effect.

To evaluate the performance of the two-stage prediction model, we will use internally validation methods via both the traditional measures, like $c$-statistic, and measures relevant to clinical usefulness.

**Publication bias** Considering that we will probably not be able to include all the relevant research works, as some studies or their results were likely not published owing to non-significant results (study publication bias and outcome reporting bias) [41, 42], we will evaluate this issue by comparing the search and screening results (as we will try to retrieve possibly unpublished reports) with the IPD we can get. If necessary, we will address it by adding the study’s variance as an extra covariate in the final IPD meta-regression model (see the section “Predicting treatment effect for patients with particular characteristics: a two-stage model”—“Stage 2: Developing a meta-regression model for treatment effects”).

**Statistical software** We will use R for our analyses. Stage 2 will be performed in a Bayesian setting using R2Jags. For the development of the baseline risk model, we will use the pmsampsize command to estimate if the available sample size is enough. We will examine the linear relationship between each one of the prognostic factors and the outcome via rcs and anova commands. The LASSO model will be developed using the cv.glmnet command. We will use the lrm command for the predefined model based on prior knowledge, and then for the penalized maximum likelihood estimation, we will use the pentrace command. For the bootstrap internal validation (both for the baseline risk score and for the two-stage prediction model), we will use self-programmed R-routines.

**Discussion** We have presented the study protocol for a prediction model of treatment effects for RA patients receiving CTZ plus MTX, using a two-stage approach based on IPD-MA.

Though there are many optional drugs in treating RA, as treatment failure is relatively high, individualizing the treatment is imperative. Many prognostic models for RA have been proposed, but no one is sufficiently satisfactory [31]. We have discovered several problems.

Most previous models focused on long-term radiographic or functional prognosis. Although they are certainly the critical outcomes that both clinicians and patients care about, the complex therapeutic changes during the long treatment process are extremely difficult to handle in developing prediction models. Thus, it usually ends up with a simplified strategy, such as taking only the initial treatment into account, which compromises the clinical interpretation and relevancy of the model. On the other hand, a good short-term treatment response is always positively associated with good long-term prognosis [43, 44]. Predicting short-term treatment effect is instructive in clinical practice; however, research is lacking. A few established “short-term” disease-activity-oriented prediction models used an outcome measured at 6 months or 12 months. The problem is, unless in active-controlled studies, there would be considerable dropouts after 3–4 months; furthermore, due to ethical issues, many trials would offer the non-responders other active treatments after 3–4 months. Under the ITT principle, patients were commonly analyzed as originally allocated; when dropouts were not negligible, imputation methods were usually used, but mostly single imputation such as non-responder imputation or last observation carried forward (LOCF) [45]. One may argue that these estimates were conservative to the intervention group though not precise. But in fact it is not always conservative for a relative effect estimate, while unbiased relative estimates are of critical interest in building personalized prediction models. As a result, in order to be methodologically rigorous, we choose the outcome measured at 3 months, when the randomization is likely kept, and which is consistent with the assessment time recommended by the guideline [1]. Additionally, thanks to the IPD, we will be able to use multiple imputation to handle missing data, rather than the single imputations used in primary RCTs.

We will use a two-stage approach to construct the prediction model using IPD-MA. Unlike the usual approach, which includes baseline features as prognostic factors and effect modifiers (through interaction terms) simultaneously, we first build a risk model for baseline factors, then treating the risk score as both a prognostic factor and an effect modifier. By doing so, overfitting
Supplementary information

Additional file 1. PRISMA-P checklist.
Additional file 2. Search Strategies.

Abbreviations
ACR: American College of Rheumatology; AE: Adverse event; CDAI: Clinical Disease Activity Index; CTZ: Celecoxib; DAS28: Disease Activity Score based on the evaluation of 28 joints; DMARD: Disease-modifying anti-rheumatic drug (bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; tsDMARDs, targeted synthetic DMARD); EPV: Events per variable; EULAR: European League Against Rheumatism; FDA: Food and Drug Administration; IPD: Individual participant data; LOCF: Last observation carried forward; MA: Meta-analysis; MTX: Methylprednisolone; OR: Odds ratio; PF: Prognostic factor; RA: Rheumatoid arthritis; RCT: Randomized controlled trial; RoB: Risk of bias; SDAI: Simplified Disease Activity Index; TNF: Tumor necrosis factor

Acknowledgements
GS has received funding from the Swiss National Science Foundation (Grant No. 179158). KC and GS acknowledged HTx project funded by the European Union’s Horizon 2020 research and innovation program under grant agreement (No. 825162). SF has received a research grant from JSPS KAKENHI Grant Number JP 20K18964.

Authors’ contributions
YL and TAF conceived the study. KC and GS designed the modeling strategy. RY and SF provided substantial contribution to the design of the study during its development. YL drafted the manuscript, and all the authors critically revised it. All authors gave final approval of the version to be published.

Funding
This study was supported by the intramural support to the Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health. The funder has no role in the study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit for publication.

Availability of data and materials
The data that support the findings of this study are available from http://vivli.org but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from http://vivli.org upon reasonable request and application, after their permission.

Ethics approval and consent to participate
This study does not require institutional review board approval and participant consent.

Competing interests
TAF reports personal fees from Mitsubishi-Tanabe, MSD, and Shinogi and a grant from Mitsubishi-Tanabe, outside the submitted work; TAF has a patent 2018-177688. GS was invited to participate in two methodological meetings about the use of real-world data, organized by Biogen and by Merck. All the other authors report no competing interests to declare.

Author details
1. Department of Health Promotion and Human Behavior, School of Public Health in the Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyoku, Kyoto 606-8501, Japan. 2. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 3. University of Statistical Genetics, Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 4. Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Received: 21 April 2020 Accepted: 28 May 2020
Published online: 12 June 2020

References
1. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshah M, van Vollenhoven R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. 2016 update. Ann Rheum Dis. 2017;76(6):960–77.
2. Committee for Medicinal Products for Human Use (CHMP): Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis. In. Edited by Agency EM, vol. CPMP/EWP/556/95 London; 2018.
3. Debray TP, Moons KG, Ahmed I, Koffi Bogba H, Rihdy MD. A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. Stat Med. 2013;32(18):3158–80.
4. Ahmed I, Debray TP, Moons KG, Rihdy MD. Developing and validating risk prediction models in an individual participant data meta-analysis. BMC Med Res Methodol. 2014;14:3.
5. Debray TP, Rihdy RD, Rovers MM, Reitmos JB, Moons KG, Cochrane IPD-AWG: Individual participant data (IPD) meta-analyses of diagnostic and prognostic modeling studies: guidance on their use. PLoS Med. 2015;12(10):e1001886.
6. Bellas M, Rovers MM, Reitmos JB, Debray TP, Inthout J. Statistical approaches to identify subgroups in meta-analysis of individual participant data: a simulation study. BMC Med Res Methodol. 2019;19(1):183.
7. Finch A, Ciurea A, Bruhlart L, Moller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C. Arthritis: Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69(2):387–93.

8. Ling S, Bluet J, Barton A. Prediction of response to methotrexate in rheumatoid arthritis. Expert Rev Clin Immunol. 2018;14(5):419–29.

9. Wijbrands C, Tak PP. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc. 2017;92(7):1129–43.

10. Spilloupolou A, Colombo M, Plant D, Nair N, Cui J, Coenens MJ, Ikari K, Yamakata H, Saevandottir S, Padyukov L, et al. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD29. Ann Rheum Dis. 2019;78(8):1055–61.

11. Norgeot B, Glicksberg BS, Trupin L, Lituiev D, Gianfrancesco M, Oskotsky B, Schmajuk G, Yazdany J, Butte AJ. Assessment of a deep learning model based on electronic health record data to forecast clinical outcomes in patients with rheumatoid arthritis. JAMA Netw Open. 2019;2(3):e190606.

12. Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ. 2018;363:k4245.

13. Riley RD, Lambert PC, Abo-Zaied G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221.

14. Debray TP, Moons KG, van Valkenhoef G, Ethimioiu O, Hummeln N, Groenwold RH, Reitsma JB. GetReal Methods Review G: Get real in individual participant data (IPD) meta-analysis: a review of the methodology. Res Synth Methods. 2015;6(4):293–309.

15. Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Sys Rev. 2017;6(1):243.

16. Fisher DJ, Copas AJ, Tierney JF, Parmar MK. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol. 2011;64(9):949–67.

17. Furukawa TA, Ethimioiu O, Weitz ES, Cipriani A, Keller MB, Kocsis JH, Klein DN, Michalak J, Salanti G, Guelps P, et al. Cognitive-behavioral analysis system of psychotherapy, drug, or their combination for persistent depressive disorder: personalizing the treatment choice using individual participant data network meta-regression. Psychother Psychosom. 2018;87(3):140–53.

18. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-ID. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-PA) 2015 statement. Sys Rev. 2015;4:1.

19. Stewart LA, Clarke M, Rogers M, Riley RD, Simmonds M, Stewart G, Tierney JF, Group P-ID. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657–65.

20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birmbaum NS, Burmester GB, Bykerk VP, Cohen MD, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.

21. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birmbaum NS, Burmester GB, Bykerk VP, Cohen MD, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010. 2010;62(9):1580–8.

22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, McShane DJ, Fries JF, Group P-ID. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):131–42.

23. Felson DT, Smolen JS, Wells G, Zhang B, van Tulip LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011; 70(3):404–13.

24. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am. 2006;32(1):19–44 viii.

25. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):593–9.

26. Aletaha D, Nell VP, Stamm T, Uffmann M, Pfleghal B, Mackold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–806.

27. Aletaha D, Ward MM, McHugh KD, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625–36.

28. Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum. 2008; 59(9):2622–31.

29. Felton DT, Anderson JJ, Boers M, Bombardier C, Forst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35.

30. Espinoza F, Fabe S, Piers YM. Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):107–18.

31. Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, Clowes M, Pandor A, Stevenson M. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technol Assess. 2018;22:6601–294.

32. Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017;19(1):68.

33. Siebers SK, Zhu F, Garcia-Garcia J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, et al. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2017;8:12460.

34. Sirme JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:k4988.

35. Burke DL, Ensr J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017;36(5):855–75.

36. Carpenter JR, Kenward MG. Missing data in randomised controlled trials: a practical guide. In: https://researchonline.lshtm.ac.uk/id/eprint/4018500. Health Technology Assessment Methodology Programme, Birmingham, p. 199; 2007.

37. Burke JF, Hayward RA, Neilson JP, Kent DM. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes. 2014;7(1):163–9.

38. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society Series B (Methodological). 1996;58(1):267–88.

39. Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, Grobbbee DE. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98(9):683–90.

40. Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE Jr, Moons KG, Collins GS. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019;38(7):1276–96.

41. Khan NA, Singh M, Spencer HJ, Tornabena RD. Randomized controlled trials of rheumatoid arthritis registered at ClinicalTrials.gov: what gets published and when. Arthritis Rheumatol 2014, 66(10):2664-2674.

42. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8).iii ix-xl, 1133.

43. Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(1 Suppl 1):e000057.

44. Dougdos M, Schmidely N, Le Bars M, Lafosse C, Schiff M, Smolen JS, Aletaha D, van Riel P, Wells G. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis. 2009;68(4):484-9.

45. Ibrahim F, Tom BD, Scott DL, Prevost AT. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. Trials. 2016;17(1):272.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.